Key Laboratory for Biorheological Science and Technology of Ministry of Education (Chongqing University), State and Local Joint Engineering Laboratory For Vascular Implants (Chongqing), Bioengineering College of Chongqing University, Chongqing, China.
Department of Radiology, Chongqing Emergency Medical Center, Chongqing, China.
J Biomed Mater Res B Appl Biomater. 2019 Apr;107(3):825-837. doi: 10.1002/jbm.b.34179. Epub 2018 Oct 8.
This study aims to design an asymmetric dual coating (ADC) on the stent by ultrasonic atomization to solve the problem of delayed endothelialization and late or very late stent thrombosis which caused by drug eluting stent (DES) with symmetric coating. Chitosan-loaded monoclonal platelet glycoprotein IIIa receptor antibody SZ-21 coating (CSC) was sprayed on inner surface of stents, and outer surface was sprayed CSC and poly(lactic-co-glycolic acid) (PLGA) loaded with docetaxel (DTX) coating (PDC). The coated surface was uniform without aggregation and no shedding phenomenon either before or after stent expanded. Fluorescence labeling has confirmed that the coating has an asymmetric structure. The cumulative release for SZ-21 and DTX was 40.11% and 27.22% within first 24 h, then DTX became the major released drug from 24 h to 7 d, after released for 28 d about 40% of the SZ-21 and 50% DTX still remained on the coated stent. It achieved that ADC can inhibit thrombosis at earlier period and inhibit vascular smooth muscle cells (VSMCs) proliferation at later period. And that ADC has good hemocompatibility and can significantly inhibit VSMCs proliferation. Finally, 4 and 12 weeks after the stent with ADC implanted into rabbit carotid arteries, it showed that the stent with ADC was safe and could effectively prevent thrombosis and in-stent restenosis. © 2018 Wiley Periodicals, Inc. J. Biomed. Mater. Res. Part B, 2018. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B: 825-837, 2019.
本研究旨在通过超声雾化技术在支架上设计一种不对称双重涂层（ADC），以解决对称涂层药物洗脱支架（DES）引起的内皮化延迟、晚期或极晚期支架血栓形成的问题。将载有壳聚糖单克隆血小板糖蛋白 IIIa 受体抗体 SZ-21 的涂层（CSC）喷涂在支架的内表面上，外表面喷涂 CSC 和载有多西紫杉醇（DTX）的聚乳酸-共-羟基乙酸共聚物（PLGA）涂层（PDC）。涂层表面均匀，支架扩张前后均无聚集和脱落现象。荧光标记已证实涂层具有不对称结构。在最初 24 小时内，SZ-21 和 DTX 的累积释放量分别为 40.11%和 27.22%，然后 DTX 从 24 小时到 7 天成为主要释放药物，释放 28 天后，涂层支架上仍有约 40%的 SZ-21 和 50%的 DTX 残留。结果表明，ADC 可以在早期抑制血栓形成，在晚期抑制血管平滑肌细胞（VSMCs）增殖。并且 ADC 具有良好的血液相容性，可以显著抑制 VSMCs 增殖。最后，在 ADC 支架植入兔颈动脉 4 周和 12 周后，结果表明 ADC 支架安全，能有效预防血栓形成和支架内再狭窄。版权所有© 2018 年 Wiley 期刊公司。J. 生物医学材料研究 B 部分：应用生物材料，2018 年。版权所有© 2018 年 Wiley 期刊公司。J 生物医学材料研究 B 部分：应用生物材料 107B：825-837，2019 年。
